Lung cancer therapeutics, Forecast, Market Analysis, Global Industry Lung cancer therapeutics Market | Page 2
Lung cancer therapeutics Market Industry Size, Global Trends, Growth,
Opportunities, Market Share and Market Forecast - 2018 to 2023
“Lung cancer therapeutics market is expected to grow at the CAGR of 13% during 2018-2023. The global
lung cancer therapeutics market is growing at a modest rate due to rise in incidence prevalence rate of
lung cancer across the globe. The adoption of lung cancer drugs and innovative lung surgeries are
expected to boost the global lung cancer therapeutics market. In addition, huge demand is created by
rising diagnostic centres across the globe.
Investment and grants from government and private players are driving the market. Successful clinical
trials and FDA approval are the key factors creating huge scope in global lung cancer therapeutics
market. Number of prescriptions for lung cancer therapeutics market drugs such as Platinol, Taxol,
Gemzar, Alimta, Iressa, Xalkori & Tarceva is increasing. Personalized medicines and drug discovery &
development has significant contribution in the growth of lung cancer therapeutics market.
In addition, there are several other factors that are driving the market to grow such as the initiative
taken by the government, rising awareness within individuals related to carcinogenic effects of smoking.
Different nations imply different fines on smoking in public places. New combine therapies are being
utilized for the treatment of the lung cancer. The market is also driven by the increase in the number of
smokers globally. As per the Tobacco Atlas organization, in the year 2014, 5.8 trillion cigarettes were
smoked globally. There are several different factors that tends to drive the market such as rising
pollution due to urbanization, changing lifestyle, increasing number of lung cancer patients, and
technological developments such as utilization of biomarkers for recognition of lung cancer.
North America and Europe has a considerable contribution to the growth of global lung cancer
therapeutics market followed by APAC region. The key driving forces include rising incidence of lung
cancer diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies
such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare
system and healthcare spending APAC region looks promising for global lung cancer therapeutics
market. Improved standard of living, infrastructural development and favorable government policies are
some other factors that will boost the APAC market. The report includes detailed market overview,
market determinants, company profiling, sector analysis, market segmentation, geographical analysis,
pipeline analysis, patent analysis, strategic recommendations, key company analysis, key findings,
analyst insights and predictive analysis of the market.
The global lung cancer therapeutics market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F.
Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung cancer therapeutics companies
are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.
Market segmentation
Global lung cancer therapeutic market by drugs includes Platinol, Taxol, Gemzar, Alimta, Iressa,
Hycamtin, Gilotrif, Taxotere, Xalkori, Navelbine, Avastin, Tarceva and Others.
Global lung cancer therapeutic market by therapy include chemotherapy, targeted therapy,
immunotherapy, radiation therapy, others.